GH Research shares surge 10.25% premarket after H.C. Wainwright upgrades to Buy and JMP Securities sets $49 price target.

GH Research surged 10.25% in premarket trading, driven by a series of positive analyst upgrades and favorable business updates. Analysts at H.C. Wainwright and JMP Securities reiterated or raised "Buy" ratings, with price targets of $45 and $49, respectively, reflecting confidence in the company’s psychedelic therapy development pipeline. Additionally, GH Research reported a $238 million cash reserve as of Q2 2023, enabling accelerated 5-MeO-DMT program advancements. These developments, combined with sustained institutional interest and bullish sentiment from multiple trusted financial outlets, reinforced investor optimism ahead of key regulatory and market milestones.